NCT04409769View on ClinicalTrials.gov

Evaluation of the Tolerance of Ceftaroline and Ceftobiprole in the Management of BJI / PJI

CompletedOBSERVATIONAL
Enrollment

22

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

May 5, 2020

Study Completion Date

May 5, 2020

Conditions
Bone and Joint InfectionAntibiotic Reaction
Interventions
OTHER

Description of use of ceftaroline and ceftobiprole

Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. Description of condition of use of thoses antibiotics in PJI and BJI

Trial Locations (1)

69004

Hospices Civils de Lyon, Lyon

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT04409769 - Evaluation of the Tolerance of Ceftaroline and Ceftobiprole in the Management of BJI / PJI | Biotech Hunter | Biotech Hunter